Abstract
The biopharmaceutical market has grown steadily since the early 1980s and today over 150 protein biopharmaceuticals have been approved for clinical use. These products often exhibit forms of immunotoxicity that often only come to light during clinical studies. The predictive value of animal studies and traditional in vitro screens is questionable, with few existing methods able to predict immunotoxicity in a way that is useful for estimating risk for entire patient populations for a specific, and often unique, product. Here, the relative merits of rational design and alternative strategies for immunotoxicity testing are considered with reference to the outcomes of preclinical and clinical studies on biopharmaceuticals. Specific reference is made to the prediction of immunogenicity using organotypic models, transgenic models of autoimmunity and immunogenicity as well as rodent models of hypersensitivity, immunosuppression and immunostimulation. The role played by human cell-based assays and in silico prediction models that have been developed and validated for the assessment of chemical classes is also appraised.
Keywords: Immunogenicity, immunosupression, immunostimulation, animal testing, organotypic, in vitro
Current Drug Safety
Title: Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment
Volume: 5 Issue: 4
Author(s): Nirmala Bhogal
Affiliation:
Keywords: Immunogenicity, immunosupression, immunostimulation, animal testing, organotypic, in vitro
Abstract: The biopharmaceutical market has grown steadily since the early 1980s and today over 150 protein biopharmaceuticals have been approved for clinical use. These products often exhibit forms of immunotoxicity that often only come to light during clinical studies. The predictive value of animal studies and traditional in vitro screens is questionable, with few existing methods able to predict immunotoxicity in a way that is useful for estimating risk for entire patient populations for a specific, and often unique, product. Here, the relative merits of rational design and alternative strategies for immunotoxicity testing are considered with reference to the outcomes of preclinical and clinical studies on biopharmaceuticals. Specific reference is made to the prediction of immunogenicity using organotypic models, transgenic models of autoimmunity and immunogenicity as well as rodent models of hypersensitivity, immunosuppression and immunostimulation. The role played by human cell-based assays and in silico prediction models that have been developed and validated for the assessment of chemical classes is also appraised.
Export Options
About this article
Cite this article as:
Bhogal Nirmala, Immunotoxicity and Immunogenicity of Biopharmaceuticals: Design Concepts and Safety Assessment, Current Drug Safety 2010; 5 (4) . https://dx.doi.org/10.2174/157488610792246037
DOI https://dx.doi.org/10.2174/157488610792246037 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Omalizumab in the Treatment of Chronic Urticaria: The Effect of Drug Co-Administration and Co-Morbidities
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Editorial (Current and Emerging Pharmacological Therapies of Ischaemic Stroke)
CNS & Neurological Disorders - Drug Targets Editorial (Hot Topic: Inflammation, Coagulation, Vascular Permeability and Thrombosis)
Current Vascular Pharmacology Hypersensitivity Reactions to Ophthalmic Products
Current Pharmaceutical Design A Practical Guide for the Treatment of Symptomatic Heart Failure with Reduced Ejection Fraction (HFrEF)
Current Cardiology Reviews Food Allergy
Current Pharmaceutical Design Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease
Current Pharmaceutical Biotechnology Cytokine and Nitric Oxide Production Following Severe Envenomation
Current Drug Targets - Inflammation & Allergy Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Allergy to Miscellaneous Household Arthropods
Protein & Peptide Letters Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review
Recent Patents on Inflammation & Allergy Drug Discovery Blood Coagulation as an Intrinsic Pathway for Proinflammation: A Mini Review
Inflammation & Allergy - Drug Targets (Discontinued) Malaria in Children - Prevention and Management
Infectious Disorders - Drug Targets Systematic Review on Infusion Reactions Associated with Chemotherapies and Monoclonal Antibodies for Metastatic Colorectal Cancer
Current Clinical Pharmacology Management of Food-Induced Anaphylaxis: Unsolved Challenges
Current Clinical Pharmacology Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry Overlooked Issues of Snakebite Management: Time for Strategic Approach
Current Topics in Medicinal Chemistry Review on Plants with Traditional Uses and Bio-activity against Hair Graying
Current Traditional Medicine Serine Proteinase Inhibitors in the Skin: Role in Homeostasis and Disease
Current Protein & Peptide Science Histamine-Dependent and -Independent Hypersensitivity Reactions to Contrast Media: The Impact of Antihistamines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry